MABQI
LIVE

Serial Number

79322137

Owner

MABQI

Attorney

Ronald M. Kachmarik

Filing Date

Jun 11, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MABQI Trademark

Serial Number: 79322137 • Registration: 6886608

MABQI is a trademark filed by MABQI on June 11, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

MABQI

460 rue Louis Pasteur

Entity Type: 99

Trademark Details

Filing Date

June 11, 2021

Registration Date

November 1, 2022

Published for Opposition

August 16, 2022

Goods & Services

Custom manufacturing of pharmaceutical products for third parties; these services exclusively in the field of antibody generation

Pharmaceutical products for treatment of metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases, cancer diseases, neurological diseases and infectious diseases; chemical preparations for medical or pharmaceutical use for treating metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases, cancer diseases, neurological diseases and infectious diseases; medical diagnostic preparations; chemical reagents for medical or veterinary use; all these goods exclusively in the field of antibody generation

Chemical products for use in industry and science; chemical preparations for scientific use, other than for medical or veterinary use; biological preparations for use in industry and science; chemical reagents other than for medical or veterinary use; chemical products for analyses in laboratories other than for medical or veterinary use; diagnostic preparations other than for medical or veterinary use; biological preparations other than for medical or veterinary use; monoclonal antibodies for scientific use; all these goods exclusively in the field of antibody generation

Intellectual property licensing; licensing of patents; legal services, namely, copyright and industrial property right licensing; all these services exclusively in the field of antibody generation

Advisory services and information services relating to diagnostic and therapeutic properties in the field of pharmaceuticals; information and advisory services in the medical field; medical services; all these services exclusively in the field of antibody generation

Research laboratory services; biological research; scientific research; clinical research; biochemical research; biotechnological research services; medical research; research in the field of pharmaceutical products; research and development of new products for third parties; technical research; engineering; technical scientific project study; research scientific project study; all these services exclusively in the field of antibody generation

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 23, 2023 FICS
FINAL DISPOSITION PROCESSED
Feb 23, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 1, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 1, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 1, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Aug 16, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 27, 2022 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 27, 2022 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 7, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 6, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 6, 2022 TROA
REFUSAL PROCESSED BY IB
Jun 6, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 16, 2022 RFCS
REFUSAL PROCESSED BY MPU
May 16, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 1, 2022 RFCR
NON-FINAL ACTION WRITTEN
Mar 31, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 2, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 16, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 12, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 8, 2021 REPR